New Stock News | Weijian Pharmaceuticals files a second time with the Hong Kong Stock Exchange. The product portfolio includes 27 commercialized drugs and one newly approved drug.

According to the latest information from the Securities Times APP, it was disclosed by the Hong Kong Stock Exchange on June 25 that Wi Jian International Holdings Group Limited (referred to as Wi Jian Medicine) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Huatai International as its exclusive sponsor. This is the company's second submission, having previously submitted a listing application on November 7, 2025. Wi Jian Medicine has established a stable and diversified product portfolio, covering a wide range of treatments for major disease areas such as kidney, blood, respiratory system, and skin diseases. As of the latest practicable date, the company's product portfolio includes 27 commercialized drugs and 1 newly approved drug.